A therapy that homes in on a specific organ represents a meaningful advance
At the University of Pennsylvania, researchers have found a way to send healing instructions directly into the deepest, most unreachable chambers of damaged lungs — a place where medicine has long arrived too late or not at all. By engineering microscopic lipid vessels that seek out lung tissue with quiet precision, the team has translated the mRNA lessons of the pandemic era into something more intimate: a therapy that listens to the organ before it speaks to it. Published in Nature Communications, the work arrives as respiratory disease remains among humanity's leading causes of death, offering a new grammar for how the body might be asked to repair itself.
- Deep lung damage from viruses, trauma, and chronic disease has long resisted treatment because conventional drugs either miss the target or arrive without direction — leaving patients with scarred, failing tissue and few options.
- The new ionizable amphiphilic Janus dendrimers, derived from natural materials, don't scatter through the body like earlier nanoparticles — they home in on lung tissue, making organ-specific mRNA delivery a clinical possibility rather than a theoretical ambition.
- Once inside the lung, the nanoparticles instruct immune cells to produce transforming growth factor beta, a molecule the body uses to repair and regenerate tissue — essentially handing the lung a blueprint for its own recovery.
- Nobel laureate Drew Weissman called this 'the birth of a new mRNA delivery platform,' noting its advantages over COVID-era vaccines: no extreme cold storage, simpler manufacturing, and a specificity that existing systems cannot match.
- The research team is already extending the platform to the spleen and other organs, signaling that the real breakthrough may not be the lung therapy itself, but the principle that nanoparticles can be engineered to find — and heal — wherever the body is most broken.
For doctors treating patients with scarred or inflamed lungs, the problem has always been architectural: damage settles deep within the organ, beyond the reach of inhaled medications and without any address for intravenous drugs to find. Viruses like COVID-19, influenza, and RSV don't simply infect — they trigger floods of inflammation, excess mucus, and tissue death that can permanently alter the delicate structures responsible for exchanging oxygen. Respiratory disease was already the third leading cause of death globally before the pandemic made the stakes impossible to ignore.
The University of Pennsylvania team's answer is a new class of lipid nanoparticles called ionizable amphiphilic Janus dendrimers, developed from natural materials by chemist Virgil Percec. Unlike the nanoparticles used in COVID vaccines, which disperse broadly through the body, these structures naturally accumulate in lung tissue. Once there, they release mRNA that instructs immune cells to produce transforming growth factor beta — a signaling molecule the body uses to repair and regenerate damaged tissue. The therapy is injectable, organ-specific, and does not require the extreme cold storage that complicated COVID vaccine distribution.
Lead author Elena Atochina-Vasserman described the targeting capability as a meaningful advance: a therapy that can home in on a specific organ represents something genuinely different from the blunt instruments medicine has relied on for deep tissue damage. Drew Weissman, a 2023 Nobel laureate and co-author, framed the work as the beginning of a new delivery platform — one that pairs organ specificity with practical manufacturing advantages, potentially accelerating the development of future mRNA therapies.
The team is already testing a similar approach in the spleen, suggesting the underlying principle is adaptable across tissues. What the research ultimately offers is a new way of thinking: mRNA delivery not as a universal tool, but as a customizable system where the vessel itself is engineered to find the place that needs healing most.
Researchers at the University of Pennsylvania have developed a new way to deliver healing instructions directly to damaged lung tissue—a problem that has long frustrated doctors treating patients with scarred or inflamed airways. The innovation combines messenger RNA with a specially engineered lipid nanoparticle, a microscopic delivery vessel that can navigate through the bloodstream and deposit its cargo precisely where it's needed. The work, published in Nature Communications, offers a proof of concept for an injectable therapy that could transform treatment for conditions ranging from severe viral infections to traumatic lung injury.
The challenge with lung disease is architectural. Damage often settles deep within the organ, in regions where inhaled medications cannot penetrate and where intravenous drugs arrive without any particular aim. A virus like COVID-19, influenza, or RSV doesn't just infect cells—it triggers a cascade of inflammation that floods the airways with fluid, spawns excess mucus, kills tissue, and scars the delicate lining meant to exchange oxygen. Whether the injury comes suddenly from a respiratory infection or accumulates over time from chronic disease, weakened lungs can become life-threatening. Before the pandemic, respiratory diseases ranked as the third leading cause of death globally, according to research published in The Lancet.
The Penn team's solution centers on a new class of lipid nanoparticles called ionizable amphiphilic Janus dendrimers, or IAJDs. These structures were derived from natural materials and discovered by Virgil Percec, a chemistry professor at Penn. What makes them different from the lipid nanoparticles used in COVID vaccines is their specificity: they naturally accumulate in lung tissue rather than dispersing throughout the body. Once the nanoparticle reaches the lung, it releases its mRNA payload, which instructs immune cells to manufacture transforming growth factor beta, a signaling molecule essential for tissue repair and regeneration.
Elena Atochina-Vasserman, a research assistant professor of infectious diseases at Penn and one of the study's lead authors, emphasized the significance of this targeting capability. Traditional intravenous drugs spread indiscriminately through the bloodstream. A therapy that can home in on a specific organ—in this case, the lungs—represents a meaningful advance in how doctors might treat deep tissue damage that conventional approaches cannot reach.
The new delivery platform offers practical advantages beyond its precision. Unlike the COVID vaccines, which must be stored at extremely cold temperatures to remain stable, these IAJDs are more forgiving in their storage requirements and simpler to manufacture. Drew Weissman, a 2023 Nobel laureate and co-author of the study, called the work "the birth of a new mRNA delivery platform with its own strengths and potential beyond the original mRNA LNPs." He noted that while existing lipid nanoparticles excel at preventing infectious diseases, this new system combines organ specificity with easier production and storage—a combination that could accelerate development of future therapies.
The researchers are already looking beyond the lungs. Percec and his colleagues, including Atochina-Vasserman and Weissman, are testing a similar approach to treat infections in the spleen, suggesting that the underlying principle—using organ-specific nanoparticles to deliver therapeutic instructions—could be adapted for other tissues throughout the body. The work was supported by the National Institutes of Health, the National Science Foundation, and the Wellcome Leap R3 program.
What emerges from this research is a template: a way to think about mRNA delivery not as a one-size-fits-all approach, but as a customizable system where the vessel itself can be engineered to seek out and concentrate in the tissue that needs healing. For patients with scarred lungs, chronic infections, or post-viral damage, that specificity could mean the difference between a therapy that works and one that never reaches its target.
Citas Notables
This research marks the birth of a new mRNA delivery platform with its own strengths and potential beyond the original mRNA LNPs— Drew Weissman, 2023 Nobel laureate and co-author
The lungs are hard-to-treat organs because both permanent and temporary damage often happen in the deeper regions where medication does not easily reach— Elena Atochina-Vasserman, research assistant professor of infectious diseases at Penn
La Conversación del Hearth Otra perspectiva de la historia
Why has lung damage been so hard to treat compared to other organs?
The lungs are deep and complex. When damage happens in the lower regions, inhaled drugs can't reach it. Even drugs in the bloodstream just circulate everywhere without any sense of where they're needed. You're essentially throwing medicine at the problem and hoping some of it lands in the right place.
So this new nanoparticle is like a GPS-guided delivery truck?
Exactly. These Janus dendrimers naturally accumulate in lung tissue. They're not random. Once they arrive, they release mRNA that tells immune cells to make a growth factor—TGF-beta—which is what the body actually uses to repair itself. You're not forcing healing. You're giving the lungs the instructions to heal.
How is this different from the COVID vaccine nanoparticles?
The COVID particles work brilliantly for what they were designed to do—trigger an immune response against a virus. But they don't target specific organs, and they need to be frozen at minus 80 degrees. These new ones are organ-specific and much easier to store and manufacture. It's the same basic idea—mRNA in a lipid shell—but engineered for a different job.
If this works for lungs, what's next?
They're already testing it in the spleen for infections. The principle is portable. You could theoretically engineer these particles to target the liver, the heart, the brain. Once you have the template, you can adapt it.
What happens to a patient who gets this injection?
The nanoparticles circulate through the bloodstream, find their way to lung tissue, and release the mRNA. The immune cells read the instructions and start producing the repair molecule. Over time, damaged tissue begins to regenerate. It's not instant, but it's targeted—which is what makes it different from anything we've had before.